Pharmaceuticals

Neurogenic Detrusor Overactivity Industry Forecast Indicating Market Size of $2.63 Billion by 2030 at 7.6% CAGR

March 23, 2026March 23, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Neurogenic Detrusor Overactivity Market Over The Period 2026–2030?

The market size for neurogenic detrusor overactivity has experienced robust growth recently. It is forecast to increase from $1.82 billion in 2025 to $1.97 billion in 2026, at a compound annual growth rate (CAGR) of 7.9%. The historical expansion of this market stems from factors including limited treatment options for NDO, a reliance on conventional surgical interventions, the rising prevalence of neurogenic bladder disorders, an expanding infrastructure of hospitals and urology clinics, and insufficient education for patients and caregivers.

The market for neurogenic detrusor overactivity is projected to experience substantial expansion over the upcoming years. This market is set to reach $2.63 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.6%. The expansion during this period can be ascribed to several factors, including the introduction of innovative pharmacological treatments, improvements in minimally invasive surgical techniques, the incorporation of neuromodulation devices, a surge in the use of continuous patient monitoring systems, and increased funding for long-term care and rehabilitation provisions. Key trends anticipated during the forecast timeframe involve a greater uptake of antimuscarinic and beta-3 adrenergic agonists, more widespread application of neuromodulation and less invasive treatments, the broadening of behavioral therapy and patient education initiatives, an intensified emphasis on urodynamic and ultrasound-based monitoring, and heightened recognition of quality of life evaluations and extended care.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24619&type=smp

Which Major Factors Are Driving The Expansion Of The Neurogenic Detrusor Overactivity Market?

The increasing occurrence of neurological disorders is projected to boost the expansion of the neurogenic detrusor overactivity market in the future. These conditions are defined as medical ailments impacting the brain, spinal cord, or nerves, resulting in issues related to movement, sensation, cognition, or various other bodily functions. The prevalence of neurological disorders is on the rise, primarily because extended lifespans enhance the likelihood of age-related brain deterioration. Neurogenic detrusor overactivity (NDO) represents a form of bladder dysfunction frequently linked with neurological conditions, including spinal cord injury, multiple sclerosis, and Parkinson’s disease. Such conditions interfere with the regular nerve communication between the brain and bladder, resulting in unintended bladder contractions. For example, in April 2024, a study released by the American Academy of Neurology (AAN), a US-based organization focused on neurology and neuroscience, indicated that global brain disorder cases are expected to reach an estimated 4.9 billion by 2050, marking a 22% increase from roughly 4 billion cases recorded in 2021. Consequently, the escalating incidence of neurological disorders is fueling expansion within the neurogenic detrusor overactivity market.

How Is The Neurogenic Detrusor Overactivity Market Divided Into Its Major Segments?

The neurogenic detrusor overactivity market covered in this report is segmented –

1) By Types: Non-Surgical Treatment, Surgical Treatment, Follow-Up Treatment

2) By Application: Adult, Child

3) By End-User: Hospitals, Urology Clinics, Rehabilitation Centers, Private Practices, Long-Term Care Facilities

Subsegments:

1) By Non-Surgical Treatment: Antimuscarinic Drugs, Beta-3 Adrenergic Agonists, Behavioral Therapy, Neuromodulation, Clean Intermittent Catheterization, Intravesical Therapies

2) By Surgical Treatment: Botulinum Toxin Injection, Augmentation Cystoplasty, Urinary Diversion, External Sphincterotomy, Artificial Urinary Sphincter Implantation

3) By Follow-Up Treatment: Urodynamic Evaluation, Ultrasound Monitoring, Laboratory Tests, Ongoing Catheterization, Repeat Botulinum Toxin Injections, Patient and Caregiver Training, Quality of Life Assessment

How Are Trends Transforming The Neurogenic Detrusor Overactivity Market Landscape?

Leading companies within the neurogenic detrusor overactivity (NDO) treatment market are concentrating on creating advanced generic therapeutics, specifically beta-3 adrenergic receptor agonists, to provide cost-effective and efficient bladder control solutions. Beta-3 adrenergic receptor agonists, such as mirabegron, operate by inducing relaxation of the detrusor muscle in the bladder, thereby enhancing bladder capacity and mitigating symptoms like urgency and incontinence. For example, in April 2024, Lupin Ltd., an India-based pharmaceutical firm, received authorization from the U.S. Food and Drug Administration (USFDA) to introduce Mirabegron, the generic equivalent of Myrbetriq, in the United States. As an innovative once-daily oral treatment, Mirabegron offers a convenient and efficacious option for managing overactive bladder (OAB) and neurogenic detrusor overactivity (NDO) in pediatric populations. This approval further solidifies Lupin’s dedication to increasing availability of high-quality, economical generic medicines across crucial therapeutic domains.

Who Are The Prominent Organizations Shaping The Neurogenic Detrusor Overactivity Market?

Major companies operating in the neurogenic detrusor overactivity market are Astellas Pharma Inc., Medtronic plc, Ipsen, Coloplast A/S, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Viatris Inc., Apotex Inc., Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Aurobindo Pharma Limited, Hugel Inc., Abbott Laboratories, Boston Scientific Corporation, Cook Medical, Convatec Group plc, B. Braun Melsungen AG, Teleflex Incorporated, Olympus Corporation, Karl Storz SE & Co. KG, Laborie Medical Technologies, Wellspect HealthCare (DENTSPLY Sirona), Hollister Incorporated, Uroplasty Inc., Endo Pharmaceuticals Inc., Ferring Pharmaceuticals, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd., Lupin Limited, Zydus Lifesciences Ltd.

Read the full neurogenic detrusor overactivity market report here:

https://www.thebusinessresearchcompany.com/report/neurogenic-detrusor-overactivity-global-market-report

Which Region Currently Holds The Largest Share Of The Neurogenic Detrusor Overactivity Market?

North America was the largest region in the neurogenic detrusor overactivity market in 2025. The regions covered in the neurogenic detrusor overactivity market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Neurogenic Detrusor Overactivity Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24619&type=smp

Browse Through More Reports Similar to the Global Neurogenic Detrusor Overactivity Market 2026, By The Business Research Company

Peripheral Neuropathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

Neurotoxin Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurotoxin-global-market-report

Diabetic Neuropathy Market Report 2026

https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795